Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionEnvestnet Asset Management Inc
Latest Disclosed Ownership503,564 shares
Latest Disclosed Value $ 224,861,550
Envestnet Asset Management Inc reports 6.77% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 4, 2026 - Envestnet Asset Management Inc filed a 13F-HR form disclosing ownership of 503,564 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $224,861,469 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 471,643 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 6.77% during the quarter. The current value of the position is $225,007,502 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 503,564 31,921 6.77 224,862 5.16 0.0602
2026-02-10 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 471,643 888 0.19 213,824 15.98 0.0634
2025-11-05 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 470,755 21,767 4.85 184,366 -7.77 0.0530
2025-08-01 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 448,988 -21,340 -4.54 199,889 -12.34 0.0583
2025-04-29 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 470,328 47,630 11.27 228,024 33.96 0.0735
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 422,698 19,630 4.87 170,220 -9.20 0.0546
2024-11-07 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 403,068 -11,992 -2.89 187,459 -3.64 0.0605
2024-08-08 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 415,060 11,751 2.91 194,547 15.40 0.0678
2024-05-13 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 403,309 -9,320 -2.26 168,587 0.41 0.0629
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 412,629 1,143 0.28 167,894 17.34 0.0694
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 411,486 105,232 34.36 143,090 32.77 0.0655
2023-08-04 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 306,254 -1,145,620 -78.91 107,774 16.22 0.0478
2023-05-11 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,451,874 1,167,674 410.86 92,731 12.99 0.0446
2023-02-07 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 284,200 14,768 5.48 82,071 5.20 0.0425
2022-11-10 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 269,432 13,885 5.43 78,011 8.33 0.0445
2022-08-03 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 255,547 -52,192 -16.96 72,011 -10.33 0.0403
2022-05-04 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 307,739 38,499 14.30 80,311 35.83 0.0404
2022-02-04 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 269,240 20,854 8.40 59,125 31.23 0.0292
2021-10-07 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 248,386 53,642 27.54 45,055 14.74 0.0247
2021-08-04 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 194,744 -13,933 -6.68 39,266 -12.44 0.0223
2021-05-04 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 208,677 19,743 10.45 44,843 0.43 0.0291
2021-02-02 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 188,934 -108 -0.06 44,653 -13.20 0.0337
2020-10-09 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 189,042 25,601 15.66 51,442 8.42 0.0456
2020-07-08 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 163,441 49,186 43.05 47,449 74.53 0.0464
2020-04-23 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 114,255 20,284 21.59 27,187 32.14 0.0322
2020-02-11 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 93,971 6,621 7.58 20,575 39.03 0.0217
2019-10-17 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 87,350 3,372 4.02 14,799 -3.90 0.0162
2019-08-02 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 83,978 3,297 4.09 15,400 3.77 0.0194
2019-05-10 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 80,681 9,146 12.79 14,841 25.20 0.0204
2019-02-12 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 71,535 58,803 461.85 11,854 383.05 0.0183
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,732 -13,821 -52.05 2,454 -45.64 0.0042
2018-08-10 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,553 8,887 50.31 4,514 56.85 0.0103
2018-05-09 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,666 -15,954 -47.45 2,878 -42.87 0.0081
2018-02-20 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 33,620 1,373 4.26 5,038 2.80 0.0112
2017-11-13 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 32,247 8,088 33.48 4,901 57.54 0.0117
2017-08-14 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,159 5,525 29.65 3,111 52.65 0.0086
2017-05-09 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,634 3,597 23.92 2,038 83.77 0.0065
2017-02-14 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 15,037 -2,668 -15.07 1,109 -28.17 0.0040
2016-11-14 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 17,705 -9,276 -34.38 1,544 -33.48 0.0060
2016-08-15 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,981 -2,069 -7.12 2,321 0.52 0.0093
2016-05-16 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 29,050 -1,997 -6.43 2,309 -40.90 0.0099
2016-02-16 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 31,047 -3,653 -10.53 3,907 8.11 0.0177
2015-11-13 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 34,700 2,553 7.94 3,614 -8.97 0.0179
2015-08-13 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 32,147 1,895 6.26 3,970 11.24 0.0189
2015-05-15 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,252 30,062 15,822.11 3,569 15,417.39 0.0185
2015-02-12 2014-12-31 13F Vertex Pharmaceuticals COM 92532F100 190 12 6.74 23 15.00 0.0002
2014-11-13 2014-09-30 13F Vertex Pharmaceuticals COM 92532F100 178 83 87.37 20 122.22 0.0002
2014-08-14 2014-06-30 13F * VERTEX PHARMACEUTICALS COM 92532F100 95 -61 -39.10 9 -18.18 0.0001
2014-05-12 2014-03-31 13F Vertex Pharmaceuticals COM 92532F100 156 -48 -23.53 11 -26.67 0.0001
2014-02-12 2013-12-31 13F Vertex Pharmaceuticals COM 92532F100 204 -400 -66.23 15 -67.39 0.0002
2013-11-12 2013-09-30 13F Vertex Pharmaceuticals COM 92532F100 604 10 1.68 46 -4.17 0.0006
2013-08-09 2013-06-30 13F Vertex Pharmaceuticals COM 92532F100 594 594 48 0.0006
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.